

Guidelines for Anti D

Document Reference No:	PTHB / MAT 042
Version No:	5
Publication Date:	21 May 2026
Review Date:	21 July 2028
Expiry Date:	21 October 2028
Author:	Antenatal Screening Governance Lead
Document Owner:	Head of Midwifery and Sexual Health
Accountable Executive:	Executive Director of Nursing, Quality, Women and Family Health
Approved By:	Women and Childrens Policies and Procedures Governance Group
Approval Date:	21 October 2025
Document Type:	Guideline
Parent Policy:	
Scope:	PTHB Midwives

Powys Teaching Health Board is the operational name of Powys Teaching Local Health Board
Bwrdd Iechyd Addysgu Powys yw enw gweithredol Bwrdd Iechyd Lleol Addysgu Powys

To ensure that you are always using the latest version of this written control document, please refer to the version on the Corporate Governance SharePoint site

Section	Contents	Page
	Evidence Base	3
	Version Control	3
	Circulated to the following for Consultation	3
1.0	Introduction	4-5
2.0	Objective	5
3.0	Equality Statement	5-6
4.0	Role/Responsibilities	6
4.1	Head of Midwifery and Sexual Health	6
4.2	Assistant Head of midwifery and Operational Team Leads	6
4.3	Women and Children's Risk and Governance Lead	6
4.4	Midwives	6-7
5.0	Antenatal Care in Powys	7
5.1	Potentially sensitising events	7-9
5.2	Administration of anti-D at 28 weeks gestation	9-10
5.3	Minimum patient identifiers to be used	10-11
5.4	Anti-D immunoglobulin administration in Powys	11
5.5	Requisition and supply of routine antenatal anti-D prophylaxis	11
5.6	Transport and receipt of anti-D at PTHB Birth Centres	11-12
5.7	Storage	12
5.8	Documentation at time of RAADP administration in Powys	12
6.0	Postnatal Anti-D administration in Powys	12-13
7.0	Women who decline Anti-D	14
8.0	Women with allergies	14
9.0	Monitoring, Compliance & Audit	14
10.0	Review and change control	14
11.0	References and Bibliography	15
12.0	Safeguarding	16
	Appendices	
1	Care Pathway	16
2	Care Pathway Administration of anti-D to Postnatal Rh (D) Negative women in Powys	17
3	Request for Rhophylac 300 (1500 iu) Record to be kept in Birth Centre	18
4	Management Pathway for Discrepant Results following cffDNA Screening	19
	Equality Impact Assessment	20

Evidence Base

[Antenatal Screening Wales Policy, Standards and Protocols](#) - updated Aug 2023 and then May 2024

[Recommendations | Antenatal care | Guidance | NICE](#)

NICE 2021

<https://www.nice.org.uk/guidance/ng201/chapter/recommendations>

Version Control

Version	Summary of Changes/Amendments	Publication Date
1	Initial Issue	May 2017
4	Full review – changes to terminology throughout	June 2023
5	Introduction of cell free DNA	21/05/2026

Circulated to the following for Consultation

Date	Role / Designation
26/6/25	Powys Midwives
26/6/25	Members of the Women and Children's Guideline Group
26/6/25	Named Midwife Safeguarding
26/6/25	PTHB Midwifery Leadership and Management team
26/6/25	Programme Coordinator Antenatal Screening Wales

Group Approved at

Date	Group
14/10/25	Maternity Guidelines Group
21/10/25	Women and Children's Policies and Procedures Governance Group

1.0 Introduction

The purpose of the provision of Anti D is to prevent babies of RhD negative women developing haemolytic disease of the newborn (HDFN). Human red blood cells carry many antigens on their surfaces. The most important of these antigens belong to the ABO system and the Rh system. The D antigen (sometimes referred to as Rhesus D negative, or RhD-) is the most important antigen of the Rh system. People with the D antigen are referred to as RhD positive, and those without it are RhD negative. A baby inherits its blood type from both biological parents. Therefore, a mother who is RhD negative can carry a baby who is RhD positive.

During pregnancy small amounts of fetal blood can enter the maternal circulation an event called feto-maternal haemorrhage (FMH). The presence of fetal D positive cells in her circulation can cause a mother who is RhD negative, to mount an immune response, producing a template antibody as well as small amounts of antibodies against the D antigen (anti-D antibodies).

The maternal antibodies produced following can attack the red blood cells of any subsequent pregnancy where there are RhD positive babies in utero, causing HDFN.

The risk of sensitisation can be reduced by administering anti-D immunoglobulin to women in situations in which FMH is likely (after delivery, miscarriage, abortion, invasive procedures or abdominal trauma). Anti-D binds to the fetal antigen and minimises its effect.

In addition, anti-D immunoglobulin is recommended to be administered routinely in the third trimester as prophylaxis against small amounts of FMH that can occur in the absence of observable sensitising events.

On the 13th of May 2024 following the recommendation by NICE 2016 [Overview | High-throughput non-invasive prenatal testing for fetal RHD genotype | Guidance | NICE](#) the implementation of offering cell free fetal DNA (CffDNA) was introduced to all eligible women who were booked for antenatal care in Wales, who were found to be Rh negative and non-sensitised to D antigen. The test predicts the fetal genotype which will avoid unnecessary treatment with a blood product (anti-D immunoglobulin) if the fetus is Rh d negative. The test can be offered to any D Negative woman who do not have anti D or anti G antibodies at booking and singleton and twin pregnancies only – up to 26+0 weeks.

The cffDNA test can be offered from 11 weeks and 2 days to 26 weeks and 0 days. If the woman has had confirmation that the baby is Rh d positive or Rh d status of the baby is inconclusive then the baby should be considered as Rh D positive and recommend anti-D immunoglobulin

The test should not be offered after 26 weeks and 0 days as this will not allow enough time for the results and for routine 28/40 anti-D appointment to be arranged as appropriate.

Cell free DNA can be offered to women who are pregnant with twins. A positive result in this case means that at least one of the fetuses is Rh d positive and anti-D can be offered. The test cannot be offered to women pregnant with higher multiples.

Potential sensitising event.

Women who have a potential sensitising event and have anti-D immunoglobulin administered prior to the offer of cffDNA screening can still have screening performed as the anti-D Ig does not interfere with the test. However, the serological antibody test at booking, prior to the cffDNA screening must be negative for D and G antibodies.

Vanished twin

CffDNA screening can be offered to a woman who has had a twin pregnancy initially, but now has a vanishing or vanished twin. However, in this group of women there is a higher chance of a false positive result if circulating cffDNA from the vanished twin

2.0 Objective

- Routine antenatal anti-D prophylaxis (RAADP) is recommended as a treatment option for all pregnant women who are RhD negative and who are not known to be sensitised to the D antigen.
- **Following the introduction of cffDNA women who have cffDNA where the fetus is predicted to be Rh d positive, or result is inconclusive anti-D prophylaxis will be recommended.**

3.0 Equality Statement

Powys Teaching Health Board Maternity Services are committed to:

- The elimination of unlawful and unfair discrimination
- The active promotion of equal opportunities for women and their families and our workforce
- The protection of the human rights of women and their families and our workforce
- The promotion of inclusive relationships between groups who share protected characteristics and those who don't
- The valuing of the diversity inherent in the communities we serve and in our workforce.

The words 'woman' and 'women' have been used throughout this document as this is the way that the majority of those who are pregnant and having a baby will identify. For the purpose of this document, this term includes girls. It also includes people whose gender identity does not correspond with their birth sex or who may have a non-binary identity. Similarly, where the term 'parents' is used, this should be taken to include anyone who has main responsibility for caring for a baby. It is recognised that there are many different family arrangements.

When translation services are required, there is the expectation that a face-to-face translator or digital interpretation services will be provided.

The Language Line App is available to all maternity staff to use for this purpose. Consideration is required with written documents and leaflets to be provided in a woman's preferred or 1st language.

For further support and advice contact PTHB Equality Team:
powys.equalityandwelsh@wales.nhs.uk

4.0 Role /Responsibilities

4.1 Head of Midwifery and Sexual Health

The Head of Midwifery and Sexual Health must:

- Ensure all staff read and understand this procedure.
- Arrange regular reviews to monitor compliance with this procedure.

4.2 Assistant Head of Midwifery and Operational Team Leads

The Assistant Head of Midwifery and Operational Team Leads must:

- Ensuring dissemination of this document to all relevant staff
- Liaising with District General Hospitals (DGH) to feedback where care has fallen outside of this guideline.

4.3 Women and Children's Risk and Governance Lead

The Women and Children's Risk and Governance Lead have responsibility for:

- Monitoring review of incidents in relation to content of this document

4.4 Midwives

All midwives working in the maternity services have responsibility for:

- Reading and being familiar with contents of this document
- Midwives are responsible for ensuring that all Rh D negative women receive verbal and written information about antenatal and postnatal anti-D prophylaxis and have the opportunity to discuss this treatment with a midwife in the antenatal period. [Blood group and antibodies \(sharepoint.com\)](#)
- Midwives are responsible for carrying adrenaline 1:1000units; to know the correct dosages in the event of an anaphylactic reaction; and to attend annual anaphylaxis and maternal resuscitation updates.
- Midwives must ensure that appropriate requisition, administration, and audit control of anti-D immunoglobulin occurs.

5.0 Antenatal Care in Powys

- All women should be offered antenatal screening for blood group and antibodies in pregnancy at booking.
- If the Woman is identified as Rh D negative the midwife will refer her to "Your blood group and pregnancy" ASW (2022) website [Bloodgroup and antibodies - Public Health Wales \(nhs.wales\)](#)
- All women to be informed of their results as soon as it's available.
- It is best practice to inform women who are RhD negative of their result early so that they can seek midwifery advice if they have a potential sensitising event.
- The woman's RhD status must be clearly documented in the antenatal handheld records and hospital records to alert other members of the multi-disciplinary team.
- A hard copy serology result form MUST be filed in the antenatal handheld records. Midwives must not administer anti-D without access to this serology form.
- Please follow Powys pathway for cell free DNA testing (See appendix)
- Please read cell Free DNA Screening Test: A guide for health professionals.

5.1 Potentially sensitising events

After **any** potential sensitising event in pregnancy the midwife will refer the woman to her transferring DGH for administration of anti-D if results of cell free DNA are not available.

Potentially sensitizing events include:

- Miscarriage/threatened miscarriage
- Antepartum haemorrhage
- Any abdominal trauma (direct/indirect, sharp/blunt, open/closed)

- Amniocentesis
- Cordocentesis
- Other in-utero therapeutic intervention/surgery
- Chorionic villus sampling
- Ectopic pregnancy
- External cephalic version
- Intrauterine death and still birth
- Termination of pregnancy
- Evacuation of molar pregnancy
- Delivery (see section 6 for Powys Births)
- Intra op cell salvage

Potentially sensitising events in pregnancies < 12 weeks gestation

- The maternal blood group and antibody screen must be performed to check D group and check for presence of immune anti-D.
- A test is not required.
- In cases of spontaneous complete miscarriage confirmed by scan where the uterus is not instrumented, or where mild painless vaginal bleeding occurs before 12 weeks, prophylactic anti-D is **not** required.
- 500iu anti-D is indicated following an ectopic pregnancy, molar pregnancy, therapeutic termination of pregnancy and in some cases of uterine bleeding where this is repeated, heavy or associated with abdominal pain.

Potentially sensitising events 12-20 weeks' gestation

- The maternal blood group and antibody screen must be performed to check D group and check for presence of immune anti-D.
- A kleihauer test is not required.
- 500iu anti-D is indicated for any potentially sensitising event listed above within 72 hours of event.
- RhD negative women presenting with continual uterine bleeding between 12- and 20-weeks' gestation should be given at least 500iu Anti-D Ig at a minimum of 6 weekly intervals.
- If there has been a PSE and the woman has not had cffDNA or is waiting on her results, then anti-D must be recommended in these circumstances to reduce the risk of sensitisation.

Potentially sensitising events from 20 weeks gestation to term

- The maternal blood group and antibody screen must be performed to check D group and check for presence of immune anti-D.
- A kleihauer test is needed.

- For any sensitising event listed above, RhD negative previously non-sensitised women should receive a minimum dose of 500iu anti-D Ig within 72 hours of event.
- Additional doses may be necessary if the FMH exceeds that covered by the standard dose.
- In the event of continual uterine bleeding which is clinically judged to represent the same sensitising event, with no features suggestive of a new presentation or a significant change in pattern or severity of bleeding, such as the presence of abdominal pain or another clinical presentation, a minimum dose of 500iu anti-D Ig should be given at 6 weekly intervals. In the event of further bleeding, estimation of FMH should be carried out of 2 weekly intervals. If the 2 weekly FMH test shows the presence of fetal cells, additional anti-D Ig should be administered to cover the volume of FMH.
- The additional dose should be offered regardless of the presence/absence of passive anti-D in maternal plasma, and the FMH retested after 48-72 hours.
- If new symptoms develop suggestive of a sensitizing event in addition to continual uterine bleeding, then it should be managed as an additional sensitizing event, with an appropriate dose of additional anti-D and estimation of FMH.

5.2 Administration of anti-D at 28 weeks gestation

- At 28 weeks, the midwife will obtain verbal consent to take bloods for red cell antibodies. **This blood test must be taken PRIOR to administration of prophylactic anti-D Immunoglobulin.**
- If anti-D has been administered to the woman in the antenatal period following a potentially sensitizing event, this information **must** be included (including the date and dose administered) on the laboratory request form, as this may affect the interpretation of the results
- The midwife will offer RAADP (Rhopylac 300: 1500IU) and obtain verbal consent for administration. Use of routine antenatal anti-D prophylaxis should not be affected by previous anti-D prophylaxis for a sensitising event in the same pregnancy. Likewise postpartum anti-D prophylaxis should not be affected by previous routine antenatal anti-D prophylaxis or antenatal anti-D following a sensitizing event.

NICE recommends at least 250iu however in Wales only the supply of 500iu is available (SHOT, 2023). Therefore, 500iu is given as per requisition. [anti-D-aide-memoire-updated-August-2023.final .pdf](#)

If there is a potentially sensitising event (PSE) at:		
< 12 weeks	12 – 20 weeks	20+ weeks
At least 500iu Anti-D given if: Surgical Intervention Termination of Pregnancy (medical or surgical) Unusually heavy bleeding Unusually severe pain Unsure of gestation	At least 500iu Anti-D given, No Kleihauer test required	Maternal blood sample taken for Kleihauer testing At least 500iu Anti-D given Further anti-D, if indicated by Kleihauer results
<p>PSEs include: Any PV Bleeding; blunt abdominal trauma (eg seatbelt injury); invasive antenatal testing (amnio, CVS); external cephalic version (attempted & successful); miscarriage; TOP; ERPC; diagnosis of intra-uterine death; stillbirth; ectopic pregnancy.</p> <p>To be effective, Anti-D should be always be given within 72 hours of PSE, however it may have some effect if given within 10 days.</p> <p>If you are unsure of gestation, always assume higher gestation when planning care.</p>		

5.3 Minimum patient identifiers to be used

All Communication and patient checks need to include minimum identifiers. It is not sufficient just to confirm the woman’s name; minimum patient identifiers must be established before taking blood and prior to administration of anti-D immunoglobulin.

The minimum patient identifiers to be used are:

- Full name
- Address (minimum 1st line)
- Date of Birth
- Hospital or NHS number.

The patient drug information leaflet that accompanies the anti-D should be offered to the woman. See Appendix 1 for care pathway.

5.4 Anti-D immunoglobulin administration in Powys

- Intramuscular anti-D Immunoglobulin is best given into the deltoid muscle.
- The place of antenatal appointments to be discussed with the woman – it is recommended that a woman who has had anti-D administered is observed for 20 minutes following the injection due to the low risk of anaphylaxis.
- Ensure the midwife has access to Adrenaline (Epinephrine) 0.5ml of 1:1000 IM into the thigh repeated every 5 minutes if necessary.

5.5 Requisition and supply of routine antenatal anti-D prophylaxis

Women who are identified as RhD negative and have consented to RAADP will have their names recorded on the Powys anti-D requisition form (Appendix 3).

An All-Wales Blood request form to be completed.

A copy of the woman's booking serology bloods indicating blood group and antibody status to be attached to the request form.

Send the completed All Wales blood request form and a copy of booking serology form to:

Blood Transfusion laboratory
Pathology
Nevill Hall Hospital
Abergavenny
NP7 7EG

A minimum of two routine working days' notice is required by the issuing blood bank.

5.6 Transport and receipt of anti-D at PTHB Birth Centres

The anti-D (Rhophylac 300: 1500iu) will be transported from the Nevill Hall blood bank in transport boxes.

These transport boxes are validated for transport for 4 hours - this will keep them within range on the transport vehicle.

The anti-D will be assigned to each patient and will be individually packed along with the appropriate traceability label within a plastic bag.

On receipt of anti-D from supplying blood bank, the accepting midwife/relevantly trained personnel must ensure that the anti-D supplied matches the Powys requisition/receipt form. If there are any discrepancies the supplying blood bank must be notified. All anti-D will be supplied on a named woman basis; under no circumstances is anti-D supplied for a specific woman to be administered to a different woman.

5.7 Storage

- The individual patient anti-D packs may be stored at an ambient room temperature not exceeding 25°C.
- When they arrive in the clinical area, they can be kept in the box, or at room temperature until given on the same day.
- If not used after this period, the anti-D must be quarantined to prevent use and arrangements made for their return to the blood bank at Nevill Hall for disposal.
- Empty transport boxes must be returned with all packaging to Nevill Hall Hospital directly after product removal.

5.8 Documentation at time of RAADP administration in Powys

- Anti-D supplied by the issuing blood bank to a specific named woman will have a corresponding traceability label attached containing full patient details. The traceability label is in two parts.
- The 'pink sticker' part of the label must be signed and dated and placed in the woman's handheld records.
- This 'blue portion' of the label must be returned to the blood bank at the earliest opportunity as confirmation of the anti D administration. Sign, date, time and tick the 'commenced' box of the 'blue portion' and return within 4 days of administration by first class post.
- Record administration on local request/receipt log (Appendix 3)
- Record administration in hospital records (tracer).
- Documentary evidence that traceability label has been returned to issuing blood bank must be maintained. (Appendix 3)

6.0 Postnatal Anti-D administration in Powys

- After the birth of a RhD negative woman a maternal blood sample is required for all women who had cffDNA screening regardless of whether the fetus is predicted to be Rh d negative or Rh d positive. This is to assess feto-maternal haemorrhage in Rh d negative women who have delivered a Rh d positive baby to establish whether the woman required additional anti-D prophylaxis. It will also be needed if a false negative result from from cffDNA screening is discovered.

Maternal blood sample to be taken within 2 hours of birth. (ASW 2019) with minimum patient identifiers used.

- A Cord blood sample is required for all Rh d negative women who had cffDNA screening regardless of whether the fetus is predicted to be Rh d Negative or Rh D positive. This is to test for Rh D group and confirm the antenatal cffDNA result. Minimum patient identifiers must be used. If the baby is RhD positive, women who are RhD negative should be offered 500iu anti-D; or a higher dose may be required if indicated by the laboratory, within 72 hours of birth. The anti-D will be supplied by the issuing laboratory on a named woman basis.
- If there are discrepant results, see management pathway (Appendix 4) for discrepant results. **NB.** *A false negative result is where screening has predicted the Rh D Group of the fetus to be negative, but the cord blood results show the infant to be Rh D positive. We anticipate approximately 5 false negative results throughout Wales in a year. This has been risk assessed and agreed as acceptable with ASW.*
- Anti D will not routinely be given following birth but will be withheld until the baby's blood group is available. The maternal and cord samples must be transported to the DGH laboratory for testing as soon as possible, considering routine transport times, weekends and bank holidays, as a taxi may need to be arranged for the transport of bloods to the DGH laboratory. The midwife must state her mobile number on the request form so that the laboratory can communicate the results and arrange transport of anti-D if required. If the midwife who has taken the maternal and cord blood is not available to receive the results; a clear written plan must be handed over to an appropriate midwife.
- The administration of postnatal anti-D including Batch number, administration dose, expiry date as well as date and time of administration must be documented in the woman's postnatal care pathway. Anti-D supplied by the issuing blood bank to a specific named woman will have a corresponding traceability label/documentation attached containing full patient details. This needs to be completed with the date and time of administration and the signature of the midwife and returned to the issuing blood bank within 4 days.
- All RhD negative women who require anti-D following a District General Hospital birth should have received anti-D prior to discharge. It is the responsibility of the midwife undertaking the first postnatal visit to ensure that anti-D has been administered.

7.0 Women who decline anti-D

- RhD-women will have sufficient information to make an informed choice about the administration of anti-D. For some women the administration of a blood product may be unacceptable, if a woman declines anti-D her decision must be respected. The implications and risks to future obstetric outcomes must be discussed and documented.
- Bloods for antibody screening will still be offered at 28 weeks gestation.
- Record on Powys requisition/receipt log that the woman has declined anti-D.
- Women may opt not to have anti-D for other reasons; for example, they are opting to be sterilised following the current pregnancy or are certain that you won't have any more children, they are certain that the father of the baby is RhD negative. (Routine testing of partner's blood group is not to be offered due to the potential complications of assumed paternity)
- Any woman who declines anti-D must have the implications to future pregnancies discussed and documented.

8.0 Women with allergies

- All midwives need to be aware of PTHB policy on Anaphylaxis. All midwives carry adrenaline of 1:1000 and are aware of the correct dosage and administration.
- Women who have been identified as having serious allergies, previous anaphylactic reaction, or latex allergies should be individually risk assessed, and advice sought prior to anti-D immunoglobulin administration. It is recommended that woman who have had previous anaphylactic reactions or have serious allergies should be given anti-D in an environment where advanced life support can be administered.

9.0 Monitoring Compliance / Audit

Compliance with these guidelines will be monitored through clinical midwifery supervision, issues raised through training days, and the Datix reporting system.

10.0 Review and Change Control

These guidelines will be reviewed every three years or sooner should changes to legislation, guidance or practice occur.

11.0 Reference and Bibliography


- Antenatal screening Wales Policy, standards, and Protocols 2023 [Standards and Protocols 2023 English amends April 2025.pdf](#)
 - British National Formulary 62 (2011) Anti-D (Rho) immunoglobulin: London: Pharmaceutical Press
- National Institute for Health and Clinical Excellence (NICE). (2016). High-throughput non-invasive prenatal testing for fetal RHD genotype. <https://www.nice.org.uk/guidance/dg25>
- National Institute for Health and Clinical Excellence (2008b) *Antenatal Care: Routine Care for the Healthy Pregnant Woman*. <https://www.nice.org.uk/guidance/ng201>
 - PROMPT (2017). Course Manual. 3rd ed.
 - PtHB/MAT 053 Antenatal Care for Uncomplicated Care NICE Guidance <https://www.nice.org.uk/guidance/ng201>
 - PtHB/MAT 056 Antenatal Screening Guidelines <https://b-s-h.org.uk/guidelines/guidelines/use-of-anti-d-immunoglobulin-for-the-prevention-of-haemolytic-disease-of-the-fetus-and-newborn>
- Public Health Wales. (2024). Information if you are pregnant and D negative blood group. <https://phw.nhs.wales/services-and-teams/screening/antenatal-screening-wales/information-resources/bloodgroup-and-antibodies-documents/information-if-you-are-pregnant-and-d-negative-blood-group/>
- Serious Hazards of Transfusion (SHOT). (2023). Anti-D Immunoglobulins (Ig) Administration in Pregnancy- an aide memoir. [https://www.shotuk.org/wp-content/uploads/2024/10/anti-D-aide-memoire-updated-August-2023.final .pdf](https://www.shotuk.org/wp-content/uploads/2024/10/anti-D-aide-memoire-updated-August-2023.final.pdf)

12.0 Safeguarding

If any safeguarding concerns or significant risk factors are identified for a unborn child or young person/vulnerable adult practitioners must follow Wales Safeguarding Procedures (2019) and SGP036 Safeguarding Policy [Policies & Written Control Documents - SGP 036 Safeguarding Policy.pdf \(sharepoint.com\)](#) . Advice and support concerning any safeguarding issue can be sought from PTHB Safeguarding Team via the Safeguarding Hub on 01686 252806 or email PowysTHB.Safeguarding@wales.nhs.uk (Monday-Friday 09:00-17:00, excluding Bank Holidays). Outside of office hours, Local Authority can be contacted on 0345 0544 847 or contact Silver on Call. All registered practitioners should access appropriate safeguarding supervision and training as per guidance. [Safeguarding Supervision \(sharepoint.com\)](#)

Appendix 1: Care Pathway


Available at: [POWYS CELL-FREE DNA PATHWAY - ANTENATAL.docx](#)



Appendix 2: Care Pathway Administration of anti-D to Postnatal Rh (D) Negative women in Powys

Available at: [POWYS CELL-FREE DNA PATHWAY - POSTNATAL.docx](#)

POWYS CELL-FREE DNA PATHWAY—POSTNATAL



Appendix 3: Request for Rhophylac 300 (1500 iu) Record to be kept in Birth Centre

Access at: [MASTER COPY - Request for Rhophylac 300 \(1500 iu\).docx](#)

Request for Rhophylac 300 (1500 iu)


Record to be kept in Birth Centre

Birth Centre

Addressograph	EDD	Date Anti D to be delivered to birth centre	Date request with hard copy of booking blood results sent to NHH	Date Anti D received	Date & time administered or other information as to fate of anti D	Traceability Label returned to NHH

Appendix 4: Management Pathway for Discrepant Results following cffDNA Screening

Access at: [Management Pathway for Discrepant Results following cffDNA Screening.docx](#)



Equality Impact Assessment

It is not mandatory to complete an Equality Impact Assessment (EIA) for a written control document. If you feel it would be of benefit, please complete the box below and attach an EIA as an appendix to this document.

Has an Equality Impact Assessment (EIA) been completed		NO
Name of the person giving this response	Antenatal Screening Governance Lead	
If NO:	N/A	
If YES:		